Night Sweats and Paxlovid in COVID-19
Night sweats are not a documented side effect of Paxlovid (nirmatrelvir-ritonavir) in the FDA label or major clinical trials, and should prompt evaluation for other causes including the natural course of COVID-19 infection itself, which commonly presents with fever and sweating. 1
Understanding the Clinical Context
Night sweats occur frequently during acute COVID-19 infection as part of the body's febrile response and inflammatory process. The 2022 ACC Expert Consensus identifies fever as most common five days after exposure to infection 2. When evaluating a patient on Paxlovid experiencing night sweats, you must distinguish between:
- COVID-19 disease manifestations (fever, inflammatory response)
- True drug adverse effects
- Complications requiring intervention
Documented Paxlovid Side Effects
According to the FDA label, the most common adverse reactions with Paxlovid (incidence ≥1% and greater than placebo) are specifically dysgeusia (altered taste) and diarrhea 1. Night sweats, diaphoresis, or hyperhidrosis are not listed among the adverse reactions in the prescribing information.
Recent pharmacovigilance data analyzing FDA adverse event reports for Paxlovid identified neurological symptoms (dysgeusia, ageusia, headache, anosmia) as the primary concerns, but did not highlight night sweats as a significant adverse event 3.
Evaluation Algorithm
Step 1: Assess timing and severity
- When did night sweats begin relative to COVID-19 symptom onset?
- When did Paxlovid treatment start (must be within 5 days of symptom onset per FDA approval) 1?
- Are night sweats accompanied by fever, rigors, or other systemic symptoms?
Step 2: Rule out COVID-19 disease progression
- Check vital signs including temperature and oxygen saturation
- Assess for worsening respiratory symptoms (dyspnea, cough, chest pain)
- Monitor for signs of clinical deterioration requiring hospitalization 2
Step 3: Consider alternative causes
- Review complete medication list for drug-drug interactions with ritonavir (a strong CYP3A inhibitor) that could cause systemic effects 1
- Evaluate for bacterial superinfection or other complications
- Consider post-acute sequelae of COVID-19 (PASC) if symptoms persist beyond 4 weeks 2
Step 4: Monitor for serious adverse reactions
- Assess for hypersensitivity reactions (anaphylaxis, serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis) 1
- Check liver function if hepatotoxicity suspected (hepatic transaminase elevations can occur with ritonavir) 1
Management Approach
For night sweats during active COVID-19 infection on Paxlovid:
Continue Paxlovid unless contraindicated - the 5-day course reduces hospitalization risk by 87% (RR 0.13) and mortality by 96% (RR 0.04) in high-risk unvaccinated patients 4
Symptomatic management of fever:
Monitor for treatment failure or complications:
- Worsening dyspnea, hypoxemia, or clinical deterioration
- Persistent high fever beyond expected disease course
- Development of new symptoms suggesting bacterial superinfection
Complete the full 5-day Paxlovid course - discontinuation due to minor symptoms like night sweats is not warranted given the significant mortality and hospitalization benefit 6, 1
Critical Pitfalls to Avoid
Do not attribute all symptoms to Paxlovid. COVID-19 itself causes fever, sweats, and systemic symptoms. The natural disease course includes fever peaking around day 5 of infection 2.
Do not stop Paxlovid prematurely. The drug shows moderate-certainty evidence for minimal treatment discontinuation due to adverse events (RR 0.49 vs placebo) 4. Only discontinue for serious hypersensitivity reactions, severe drug-drug interactions, or clinically significant adverse events 1.
Do not miss serious complications. While evaluating benign symptoms like night sweats, remain vigilant for signs of clinical deterioration, hepatotoxicity (from ritonavir component), or hypersensitivity reactions that require immediate intervention 1.
Monitor for COVID-19 rebound. Approximately 6-8% of patients may experience symptom recurrence after completing Paxlovid, though this does not appear significantly different from placebo-treated patients 7. If symptoms worsen after treatment completion, reassess for disease progression versus rebound.
Special Populations
For patients with moderate renal impairment (eGFR 30-60 mL/min), dose reduction to 150 mg nirmatrelvir with 100 mg ritonavir twice daily is required 1. This does not change the adverse effect profile but requires monitoring.
Female patients may have higher rates of seeking medical care following Paxlovid treatment (OR 4.6), though this relates to overall medical utilization rather than specific adverse effects 8.